JP2013528563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528563A5 JP2013528563A5 JP2012544363A JP2012544363A JP2013528563A5 JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5 JP 2012544363 A JP2012544363 A JP 2012544363A JP 2012544363 A JP2012544363 A JP 2012544363A JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic composition
- composition according
- retinal
- retinopathy
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 230000000007 visual effect Effects 0.000 claims 7
- 208000017442 Retinal disease Diseases 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 5
- 210000001525 retina Anatomy 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010059239 Leukaemic retinopathy Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 206010033708 Papillitis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010003074 arachnoiditis Diseases 0.000 claims 1
- 206010063452 arteriosclerotic retinopathy Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000012286 optic choroid disease Diseases 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 201000002166 optic papillitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004382 visual function Effects 0.000 claims 1
Images
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32333810P | 2010-04-12 | 2010-04-12 | |
| US32334210P | 2010-04-12 | 2010-04-12 | |
| US61/323,342 | 2010-04-12 | ||
| US61/323,338 | 2010-04-12 | ||
| US32681110P | 2010-04-22 | 2010-04-22 | |
| US61/326,811 | 2010-04-22 | ||
| US36294510P | 2010-07-09 | 2010-07-09 | |
| US61/362,945 | 2010-07-09 | ||
| US40823710P | 2010-10-29 | 2010-10-29 | |
| US61/408,237 | 2010-10-29 | ||
| PCT/JP2011/059479 WO2011129461A1 (en) | 2010-04-12 | 2011-04-12 | Method and ophthalmic composition for treating retinal disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015194346A Division JP2016026182A (ja) | 2010-04-12 | 2015-09-30 | 網膜疾患を処置するための方法および眼科用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528563A JP2013528563A (ja) | 2013-07-11 |
| JP2013528563A5 true JP2013528563A5 (enExample) | 2014-05-29 |
| JP5878128B2 JP5878128B2 (ja) | 2016-03-08 |
Family
ID=44798822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547193A Expired - Fee Related JP5686819B2 (ja) | 2010-04-12 | 2011-04-12 | 黄斑浮腫を処置するための医薬組成物 |
| JP2012544363A Active JP5878128B2 (ja) | 2010-04-12 | 2011-04-12 | 網膜疾患を処置するための方法および眼科用組成物 |
| JP2015194346A Pending JP2016026182A (ja) | 2010-04-12 | 2015-09-30 | 網膜疾患を処置するための方法および眼科用組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547193A Expired - Fee Related JP5686819B2 (ja) | 2010-04-12 | 2011-04-12 | 黄斑浮腫を処置するための医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015194346A Pending JP2016026182A (ja) | 2010-04-12 | 2015-09-30 | 網膜疾患を処置するための方法および眼科用組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110275711A1 (enExample) |
| EP (2) | EP2558104A4 (enExample) |
| JP (3) | JP5686819B2 (enExample) |
| KR (2) | KR20130099812A (enExample) |
| CN (2) | CN102946883A (enExample) |
| AR (1) | AR080888A1 (enExample) |
| CA (2) | CA2795723A1 (enExample) |
| TW (2) | TW201141486A (enExample) |
| WO (2) | WO2011129457A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2780650A1 (en) * | 2009-11-27 | 2011-06-03 | R-Tech Ueno, Ltd. | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method |
| CN103596572A (zh) * | 2011-04-12 | 2014-02-19 | 株式会社·R-技术上野 | 水性眼用组合物 |
| HK1205461A1 (zh) * | 2012-02-22 | 2015-12-18 | Trustees Of Tufts College | 用於眼部传输治疗剂的组合物和方法 |
| AU2017317129B2 (en) * | 2016-08-24 | 2020-04-30 | National Institute Of Biological Sciences, Beijing | Entacapone-related compounds to treat macular degeneration |
| US12702683B2 (en) | 2019-01-03 | 2026-08-11 | Mesoblast International Sárl | Method for improving visual acuity |
| EP4667578A3 (en) * | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| JP7664239B2 (ja) * | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス， インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| BR112023022705A2 (pt) | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| FI131849B1 (en) * | 2024-09-10 | 2026-01-09 | Pixieray Oy | METHOD AND OPTICAL DEVICE FOR MONITORING THE USE OF EYE DROPS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU771130B2 (en) * | 2000-01-18 | 2004-03-11 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| WO2003020283A2 (en) * | 2001-08-29 | 2003-03-13 | Novartis Ag | Method for treating diabetic retinopathy |
| JP5222462B2 (ja) * | 2003-08-21 | 2013-06-26 | スキャンポ・アーゲー | 眼科用組成物 |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| US20080233053A1 (en) * | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
| US20100087540A1 (en) * | 2008-10-07 | 2010-04-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition |
-
2011
- 2011-04-12 AR ARP110101238A patent/AR080888A1/es unknown
- 2011-04-12 TW TW100112624A patent/TW201141486A/zh unknown
- 2011-04-12 EP EP11768978.6A patent/EP2558104A4/en not_active Withdrawn
- 2011-04-12 CN CN2011800290140A patent/CN102946883A/zh active Pending
- 2011-04-12 JP JP2012547193A patent/JP5686819B2/ja not_active Expired - Fee Related
- 2011-04-12 WO PCT/JP2011/059474 patent/WO2011129457A1/en not_active Ceased
- 2011-04-12 US US13/084,982 patent/US20110275711A1/en not_active Abandoned
- 2011-04-12 CN CN201180028968XA patent/CN102933217A/zh active Pending
- 2011-04-12 WO PCT/JP2011/059479 patent/WO2011129461A1/en not_active Ceased
- 2011-04-12 CA CA2795723A patent/CA2795723A1/en not_active Abandoned
- 2011-04-12 KR KR1020127029562A patent/KR20130099812A/ko not_active Withdrawn
- 2011-04-12 CA CA2795720A patent/CA2795720A1/en not_active Abandoned
- 2011-04-12 TW TW100112738A patent/TW201204366A/zh unknown
- 2011-04-12 EP EP11768976.0A patent/EP2558103A4/en not_active Withdrawn
- 2011-04-12 KR KR1020127029449A patent/KR20130050939A/ko not_active Withdrawn
- 2011-04-12 US US13/084,927 patent/US20110275715A1/en not_active Abandoned
- 2011-04-12 JP JP2012544363A patent/JP5878128B2/ja active Active
-
2015
- 2015-09-30 JP JP2015194346A patent/JP2016026182A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4360709A3 (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
| MY176514A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2015526467A5 (enExample) | ||
| RU2015117536A (ru) | Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний | |
| RU2012151575A (ru) | Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин | |
| WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
| MX2019008963A (es) | Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico. | |
| Xin et al. | Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| TW201141486A (en) | Pharmaceutical composition for treating macular edema | |
| ME02608B (me) | Kombinacija, komplet i postupak snižavanja intraokularnog pritiska | |
| NZ594728A (en) | Use of deferiprone for treatment and prevention of iron-related eye disorders | |
| HRP20192256T1 (hr) | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta | |
| Day et al. | Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension | |
| JP7461667B2 (ja) | ナノ低分子ペプチドｆｈ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用 | |
| JP2012505928A5 (enExample) | ||
| JP2014521648A5 (enExample) | ||
| Querques et al. | Intravitreal pegaptanib sodium for Irvine-Gass syndrome | |
| JP2015027980A5 (enExample) | ||
| Bennet | Pegaptanib for the treatment of ischemic retinopathy in patients with diabetes and retinal vascular occlusive disorders | |
| CN110496130B (zh) | 一种防治糖尿病性视网膜病变的药物组合物 | |
| WO2026078034A1 (en) | Sitagliptin for use in retinal diseases with neovascularization | |
| LIU et al. | Bevacizumab-assisted surgery in the treatment of severe proliferative diabetic retinopathy | |
| HK1189820A (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
| AU2023221950A1 (en) | Treatment of anatomical and functional retinal atrophies |